Amanda Davis-Houchen
Family · Jeffersonville, INNPI 1538396155
Payments from drug & device makers
Across 315 payments — averaging $14.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$556
- Gilead$501
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$378
- Lundbeck LLC$193
- Indivior Inc.$168
- plus $1K from 21 others
What the payments were for
- Food & beverage$4,618100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 146 | $1,418 |
| GSK | 24 | $556 |
| Gilead | 24 | $501 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $378 |
| Lundbeck LLC | 11 | $193 |
| Indivior Inc. | 9 | $168 |
| Neurocrine Biosciences, Inc. | 10 | $151 |
| Otsuka America Pharmaceutical, Inc. | 7 | $143 |
| Exact Sciences | 6 | $134 |
| AstraZeneca | 9 | $127 |
| Alkermes, Inc. | 6 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $111 |
| Johnson & Johnson | 4 | $89 |
| Merck | 3 | $71 |
| Novo Nordisk | 4 | $65 |
| Lilly USA, LLC | 4 | $61 |
| Idorsia Pharmaceuticals US Inc | 4 | $54 |
| Vanda Pharmaceuticals Inc. | 3 | $51 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Pfizer | 2 | $36 |
| Verona Pharma, Inc. | 2 | $34 |
| Eisai Inc. | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Impel Pharmaceuticals Inc. | 1 | $15 |
| Amgen | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Descovy$120
- TRELEGY ELLIPTA$118
- BLENREP$109
How this compares
$4,629 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 23 | $98,004 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $55,690 |
| FarxigaDapagliflozin Propanediol | 32 | $25,736 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $15,744 |
| OzempicSemaglutide | 15 | $14,763 |
| MounjaroTirzepatide | 11 | $12,052 |
| LinzessLinaclotide | 19 | $10,784 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $9,480 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $9,096 |
| JardianceEmpagliflozin | 15 | $8,878 |
| Fenofibrate | 30 | $7,776 |
| Midodrine Hcl | 34 | $6,360 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 15 | $4,637 |
| SteglatroErtugliflozin Pidolate | 14 | $4,601 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 18 | $3,882 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $501 | $98,00423 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arexvy, Shingrix | $556 | $73,690119 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $127 | $41,48056 claims |
| Novo NordiskOzempic | $65 | $14,76315 claims |
| Lilly USA, LLCMounjaro | $61 | $12,05211 claims |
| AbbVieLinzess | $1,418 | $10,78419 claims |
| MerckSteglatro | $71 | $4,60114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.
Other family in Jeffersonville
- Rhonda StameyJeffersonville$28K
- Michelle VissingJeffersonville$18K
- Stacy GarciaJeffersonville$17K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.